Device specific vigilance guidance: Cardiac Implantable Electronic Devices (CIEDs)

AI Summary

This guidance document from the UK Medicines and Healthcare products Regulatory Agency (MHRA) establishes reporting protocols for manufacturers of cardiac implanted electronic devices (CIED), including pacemakers and defibrillators. The framework aligns with SI 2024 No.1368 and international standards to ensure robust post-market surveillance. The document specifies that manufacturers must report individual incidents involving death, cardiac perforation, or critical device failures—such as lead fractures and therapy delivery failures—within statutory timescales. Less critical issues, including premature battery depletion, insulation failures, and telemetry malfunctions, may be reported through Periodic Summary Reports (PSR) on a three- or six-month cycle. Additionally, manufacturers are required to monitor and report significant trends in complications such as device-related infections, strokes, or electrode displacements. Required actions for companies include categorizing incidents using International Medical Device Regulators Forum (IMDRF) codes and ensuring internal monitoring systems reflect current clinical guidelines from the European Society of Cardiology and the British Heart Rhythm Society. Compliance requires strict adherence to these reporting schedules to maintain device safety and efficacy standards.